Here are some of its competitors that are already FDA approved for weight management: Liraglutide (Saxenda) : This injectable medication is a once-daily GLP-1 receptor agonist approved for chronic weight management in adults with a body mass index (BMI) of 30 or greater (obesity) or 27 or greater (overweight) with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol
Why this matters: The overlap between type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) has reached epidemic proportions
RC By Rachel Cohrs Zhang, Madison Muller and Naomi Kresge, Bloomberg November 06, 2025 12:00 PM CST Featured Stories Mergers & Acquisitions Intermountain to buy Surgery Partners stakes in 2 Idaho hospitals The deal values the facilities at an estimated $1.15 billion
Research on peptide preparation methods shows that sonication at room temperature can improve dissolution without causing degradation for most peptides [4]
Medication should not be stopped, restarted, or changed without discussion with the prescribing clinician
GLP-1 hair loss is real
